



# Global Health L i m i t e d

**August 07, 2025**

**Ref:- GH/2025-26/EXCH/42**

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub:** Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the first quarter ended June 30, 2025 Results.

Kindly take the above on record.




Thanking you,

Yours faithfully

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**



**Medanta reports highest ever quarterly Total Income and EBITDA in Q1 FY2026**

- Total Income of INR 10,513 million; up by 19.1% y-o-y
- EBITDA of INR 2,553 million; up by 22.6% y-o-y with margins of 24.3%
- Net Profit of INR 1,590 million; up by 49.6% y-o-y with margins of 15.1%

**Gurugram, August 07<sup>th</sup>, 2025:** Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its unaudited consolidated financial results for the quarter ending 30<sup>th</sup> June, 2025.

**Consolidated Highlights of the Quarter Ended 30<sup>th</sup> June, 2025 (Q1 FY2026)**

- Consolidated Total Income of INR 10,513 million, grew by 19.1% y-o-y
- EBITDA was INR 2,553 million, growth of 22.6% y-o-y
- EBITDA margins improved to 24.3% compared to 23.6% in Q1 FY25
- Profit After Tax was INR 1,590 million, with improved PAT margins of 15.1%
- Occupied bed days increased by 13.3%, representing an occupancy of 63.2% on increased bed capacity
- ARPOB grew by 4.0% to INR 66,584 in Q1 FY26 driven by increase in realization in Gurugram unit and change in speciality mix
- In-patients count increased by 14.2% and Out-patients count increased by 13.1% y-o-y
- Matured hospitals revenue was INR 7,006 million, growth of 10.7% on y-o-y basis. EBITDA was INR 1,640 million, growth of 6.7% y-o-y
- Developing hospitals revenue was INR 3,219 million, growth of 35.9% on y-o-y basis. EBITDA was INR 942 million, strong growth of 59.8% y-o-y
- During the period, International Patients Revenue increased by 33.8% y-o-y to INR 636 million, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 21.6% y-o-y to INR 404 million

**Commenting on Q1 FY2026 results, Mr. Pankaj Sahni, Group CEO and Director said:**

“I am pleased to report another strong quarter, delivering our highest ever Total Income and EBITDA with year-on-year growth of 19% and 23% respectively. This robust performance was driven by increased patient volumes and improved realizations, with consistent growth across mature hospitals as well as Lucknow and Patna hospital.

We successfully operationalized our 110-bed hospital in Ranchi in July 2025 and remain on track to commission our upcoming 550-bed facility in Noida in Q2 FY2026. Backed by a balanced portfolio of assets and a strong balance sheet, we are well-positioned to execute our long-term growth strategy and further expand the Medanta model of care across the region.”

### Key Developments – Q1 FY2026

- Development of a 550 bedded Noida hospital is in full swing and is expected to be operational with 300 beds in Q2 FY2026
- Newly built 110 bedded hospital in Ranchi, operationalized in July 2025, expanding regional presence in underserved market
- 20 new beds added in Patna and construction of additional beds in tower B is in progress
- On-boarded 150+ doctors including 30+ senior clinicians across Medanta network, to strengthen clinical capabilities

### Financial Highlights: Q1 FY2026

INR million	Quarter			Y-o-Y Growth %
	Q1 FY25	Q4 FY25	Q1 FY26	
<b>Revenue from operations</b>	<b>8,611</b>	<b>9,312</b>	<b>10,308</b>	<b>19.7%</b>
Other income	219	229	205	(6.7)%
<b>Total income</b>	<b>8,830</b>	<b>9,542</b>	<b>10,513</b>	<b>19.1%</b>
Cost of materials consumed	2,089	2,136	2,391	14.5%
Employee benefits expense	3,197	3,356	3,852	20.5%
Other expenses	1,462	1,573	1,717	17.4%
<b>EBITDA</b>	<b>2,082</b>	<b>2,476</b>	<b>2,553</b>	<b>22.6%</b>
<b>EBITDA Margins %</b>	<b>23.6%</b>	<b>26.0%</b>	<b>24.3%</b>	<b>70 bps</b>
ESOP Expenses	0	0	79	na
<b>EBITDA after ESOP Expenses</b>	<b>2,082</b>	<b>2,476</b>	<b>2,474</b>	<b>18.8%</b>
Finance costs	180	150	138	(23.3)%
Depreciation and amortization expense	466	493	451	(3.2)%
Exceptional item	0	499	(196)	na
<b>Profit before tax</b>	<b>1,437</b>	<b>1,334</b>	<b>2,081</b>	<b>44.9%</b>
Tax expenses	374	321	492	31.5%
<b>Profit after tax</b>	<b>1,063</b>	<b>1,014</b>	<b>1,590</b>	<b>49.6%</b>

Notes:

1. EBITDA represents EBITDA before ESOP expenses
2. In Q1 FY26, PAT is higher due to non-recurring exceptional income of INR 196 million arising due to reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL

\*\*\*\*\*

**About Global Health Limited (Medanta)**

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 3,062 installed beds as on June 30, 2025. It also has one hospital under-construction in Noida and four upcoming hospitals in Mumbai, New Delhi (Pitampura), South Delhi (GK) and Guwahati. The Company provides healthcare services in over 30 medical specialties and engages over 2,000 + doctors led by highly experienced department heads.

For more information visit [www.medanta.org](http://www.medanta.org) or contact:

**Global Health Limited****Ravi Gothwal**[ravi.gothwal@medanta.org](mailto:ravi.gothwal@medanta.org)

Tel: 0124 – 4141 414

**Bhushan Khandelwal**[bhushan.khandelwal@medanta.org](mailto:bhushan.khandelwal@medanta.org)

Tel: 0124 – 4141 414

**Safe Harbour Disclaimer**

This press release, apart from historical information, contains some “forward-looking statements” including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.